Vireo Growth (VREOF) Free Cash Flow (2020 - 2026)
Vireo Growth (VREOF) posted Free Cash Flow of $1.1 million for Q1 2026, down 87.49% sequentially from $8.8 million in Q4 2025, and up 124.44% YoY from $490099.0 in Q1 2025.
Vireo Growth (VREOF) Free Cash Flow (2020 - 2026) Analysis & Trends
Vireo Growth has reported Free Cash Flow for 7 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 124.44% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.0 million (up 21.89% YoY) and the FY2025 annual result came in at -$24.6 million, down 12.23% from the prior year.
- Free Cash Flow slipped to $1.1 million in Q1 2026 per VREOF's latest filing, from $8.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $8.8 million in Q4 2025 and troughed at -$20.5 million in Q3 2025.
- A 5-year average of -$4.4 million and a median of -$4.0 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow tumbled 597.52% in 2024, then jumped 195.96% in 2025.
- Over 5 years, Free Cash Flow stood at -$6.7 million in 2022, then surged by 58.59% to -$2.8 million in 2023, then sank by 228.21% to -$9.2 million in 2024, then surged by 195.96% to $8.8 million in 2025, then slumped by 87.49% to $1.1 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $1.1 million, $8.8 million, and -$20.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Vireo Growth | 487.39 Mn | 345.09 Mn | 95.30 Mn | -105.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 8.79 Mn |
| Dec 31, 2025 | 8.79 Mn |
| Sep 30, 2025 | -20.45 Mn |
| Sep 30, 2025 | -20.45 Mn |
| Jun 30, 2025 | -8.46 Mn |
| Jun 30, 2025 | -8.46 Mn |
| Mar 31, 2025 | -4.50 Mn |
| Mar 31, 2025 | -4.50 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Sep 30, 2024 | -7.48 Mn |
| Sep 30, 2024 | -7.48 Mn |
| Jun 30, 2024 | -3.20 Mn |
| Jun 30, 2024 | -3.20 Mn |
| Mar 31, 2024 | -2.09 Mn |
| Mar 31, 2024 | -2.09 Mn |
| Dec 31, 2023 | -2.79 Mn |
| Dec 31, 2023 | -2.79 Mn |